<DOC>
	<DOCNO>NCT00657488</DOCNO>
	<brief_summary>The objective study show thalidomide dose 100 mg/d ( remedial treatment dexamethasone progression occur ) equivalent term efficacy thalidomide 400 mg/d ( remedial treatment dexamethasone progression occur ) treatment refractory relapse multiple myeloma least two course treatment . The use thalidomide 100 mg/d reduce side effect improve safety treatment .</brief_summary>
	<brief_title>Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day Relapse Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient 18 year inform potential risk side effect treatment sign informed consent take part various aspect study . Having refractory relapse multiple myeloma least two course treatment . The patient refractory relapse multiple myeloma single course treatment include alkylating drug , include alternative treatment . Concerning thalidomide : Agreement use introduction effective contraception patient : 1 . For woman childbearing potential Oral estroprogestogen contraception introduce least 1 month first administration thalidomide , continue first menstruation follow end treatment , partner use condom . Qualitative serum test betaHCG negative : do Day 2 3 menstrual cycle 1st prescription thalidomide ; context spaniomenorrhea amenorrhea test do within 3 day 1st prescription thalidomide . 2 . For postmenopausal woman 1st situation : Known sterility due : total hysterectomy ; total ovariectomy ; total salpingectomy 2nd situation : Natural menopause amenorrhea least 1 year negative progestagen test plasma FSH &gt; 50 IU/l 3 . For men : Throughout duration treatment 3 month end protocol ( i.e . one spermatogenesis cycle ) , sexual intercourse must always protect use condom . Pregnant breastfeed woman childbearing potential use effective method contraception lack protection sexual intercourse men . Patients already receive treatment thalidomide . Contraindication thalidomide . Patient absolute contraindication dexamethasone . Patient history deep vein thrombosis take effective oral anticoagulation ( anticoagulant must continue throughout entire study ) . Performance index equal 3 , unless patient bedridden result progress myeloma . Any situation permit adequate followup study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Myeloma , Thalidomide , dose , dexamethasone</keyword>
</DOC>